October #106 : Alzheimer’s Drug Does HIV - by Liz Highleyman

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Crime no. 69

Who’s Afraid of HU?

Six Nights in Bangkok

Their Patients, Their People

Thar She Blows!

HU Handbook

Top Black MDs

Heartbreak Hotel

Quilt Trip


No PEP Rally


Show & Tell



Pos & Neg

Meth-od Actor

West Denial Virus

Bangkok Big Top


Private Parts

Forbidden Grapefruit

Quick Study: Prostate

Alzheimer’s Drug Does HIV

Body Eclectic: Lungs

Get Flu-ent

If You Knew Sushi


Trip or Treat

Scared Straight

Hitched & Bewitched


Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

October 2004

Alzheimer’s Drug Does HIV

by Liz Highleyman

Can a new med ease HIV dementia and PN pain?

Germans have long used Namenda (memantine) for dementia and Parkinson’s disease, and the U.S. approved it last fall for Alzheimer’s. Some diabetics take it for neuropathy—and a few HIVers pop it, too.

“Namenda saved my life,” says Miami’s F.D.R. “Fluffy” Sullivan. Now 48, Sullivan began having HIV-related cognitive kinks 10 years ago: “I’d throw my keys away with the trash and forget what I was talking about.” Then peripheral-neuropathy (PN) pain landed him in a wheelchair, so he steered straight for a Namenda trial in 1997. Within a month, he’d ditched his chair and cane. “Namenda made me young again,” he raves. (His seven-drug HAART combo helps, too.)

Namenda protects brains injured by Alzheimer’s, strokes or HIV. These illnesses cause neurons to release too much glutamate (an amino acid that helps you learn and remember), flooding and damaging brain cells. Namenda binds to some of the brain’s receptors, blocking the glutamate glut; those receptors may also play a role in how neuropathy pain is felt.

In lab and animal studies, Namenda performed as promised, but Fluffy’s 140-person ACTG 301 trial proved statistically insignificant. Yet 301 lasted just 16 weeks; in Alzheimer’s trials, the drug didn’t shine until 24 weeks. And “among HIVers with detectable virus in their cerebrospinal fluid, the rate of neurological progression was significantly lower in the memantine group,” says lead investigator Bradford Navia, MD. Though Namenda had “no obvious effect” on neuropathy, it didn’t interfere with HIV meds and side effects were minor—mostly insomnia and agitation. It can cause hallucinations, so “be careful [with] patients predisposed to neuropsychiatric problems,” Navia says.

Experts agree that effective HAART is the first line against HIV dementia. But adding Namenda may help older HIVers, those with resistant virus and others at risk for cognitive decline. “Given its good safety profile, I’d probably prescribe it,” Navia says. “There’s nothing to lose.”

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.